<P>&nbsp;</P> <P align=justify><STRONG><STRONG><A title="" href="https://www.aderly.com/centre-recherche-et/biotechnology-cluster-lyon,p,21,EN.jsp" target=_blank>The Lyon-Gerland site, one of Europe&#8217;s largest science parks dedicated to the life sciences and innovative technologies</A></STRONG>, continues to be coveted for large-scale biotech projects</STRONG>. This complex, which features 30 public research laboratories and 2,000 companies, is the <STRONG>epicenter of the <A title="" href="http://www.lyonbiopole.org/" target=_blank>Lyonbiop&#244;le world competitiveness cluster</A></STRONG>, a leader in the fight against human and animal infectious diseases and cancers. </P> <P align=justify><BR><A title="" href="https://www.aderly.com/lyon-economic-news/france-pharmaceutique-news-BIOVISION-2013-IN-LYON,n,6907,EN.jsp" target=_blank>During BioVision, the World Life Sciences Forum held at the end of March 2013</A>, G&#233;rard Collomb, Senator and Mayor of Lyon, proposed a number of ideas, including <STRONG>the transfer of the International Agency for Research on Cancer (IARC/WHO) to Gerland.</STRONG> </P> <P align=justify><BR>Another major project involves <STRONG>the extension of the Jean M&#233;rieux Biosafety Level 4 laboratory, which should be expanded by 200 sq. m. before the end of 2013</STRONG> in order to house a biological resource center. An even more ambitious project is <STRONG>the Gerland 2 laboratory, initiated by Aguettant, a 10,000 sq. m. facility that will house the company&#8217;s headquarters, a production facility, a laboratory and an R&amp;D center. </STRONG></P> <P align=justify><BR><STRONG><STRONG><A title="" href="https://www.aderly.com/france-biotechnologies-biotech/company-lyon-genzyme-biotechnology-biotech,p,122,EN.jsp" target=_blank>Genzyme, a subsidiary of Sanofi</A></STRONG>, will also welcome a new cutting-edge platform for the production of products for Transgene</STRONG>. <A title="" href="https://www.aderly.com/france-pharmaceutique/company-lyon-sanofi-aventis-pharmaceutical,p,130,EN.jsp" target=_blank>Sanofi, a world leader in vaccines</A> and Merial, specialized in veterinary medicines and vaccines will <STRONG>bring their activities together at a single facility in 2016</STRONG>. In the words of Sanofi Pasteur CEO Olivier Charmeil at a recent press conference, this initiative aims to &#8220;pool resources and better capitalize on synergies&#8221;.</P> <P align=justify><BR><STRONG>All of these organizations and projects play an active role in the life of Lyonbiop&#244;le, which has had a very positive track record since it was founded</STRONG>. The competitiveness cluster is a key ambition of G&#233;rard Collomb, who has stated he would like &#8220;to place the Lyon metropolitan area amongst the world&#8217;s top 10 major hubs for healthcare and biotechnology in the coming years".</P> <P>&nbsp;</P>